<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="210164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351572</url>
  </required_header>
  <id_info>
    <org_study_id>GI-5-0055</org_study_id>
    <nct_id>NCT00351572</nct_id>
  </id_info>
  <brief_title>Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients</brief_title>
  <official_title>Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      This study will determine whether a new diagnostic test called the Cell Search Assay can
      detect circulating colon cancer cells in patients who have had surgery for colon cancer and
      had visible cancer removed. Other parts of the study will look at whether the presence of
      the circulating tumor cells in blood predicts whether a patient will have their colon cancer
      return.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colon Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cell Search Assay</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic and any other interested parties
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage II or III colon cancer

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Sawyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <lastchanged_date>April 15, 2011</lastchanged_date>
  <firstreceived_date>July 11, 2006</firstreceived_date>
  <keyword>colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
